. 2013 Jun 10;104(8):1074–1082. doi: 10.1111/cas.12186

Table 2.

Association analysis of single nucleotide polymorphisms (SNPs) with different chemotherapeutic drugs/drug subgroups known to induce severe neutropenia/leucopenia

CHR	SNP	BP	RA	NRA	RAF_Case	RAF_Ctrl	P_allelic	P_dom	P_rec	Pmin	OR	L95	U95	Gene	rel.loci
Cyclophosphamide
16	rs2519974^a	22889186	T	C	0.503	0.381	2.52E‐04	4.35E‐06	2.77E‐01	4.35E‐06	1.647	1.264	2.146	HS3ST2	0
1	rs10922438^a	198469162	T	C	0.214	0.106	6.01E‐06	1.71E‐05	7.10E‐02	6.01E‐06	2.301	1.608	3.293	ATP6V1G3	23190
19	rs3745571^a	6475613	T	C	0.778	0.670	4.05E‐04	7.72E‐06	1.00E+00	7.72E‐06	1.730	1.276	2.345	DENND1C	0
All platinum‐based drugs
15	rs4886670^a	75449674	A	C	0.320	0.227	9.86E‐07	1.43E‐05	8.14E‐04	9.86E‐07	1.605	1.330	1.937	RPL36AP45	29318
19	rs33428^a	30937843	G	A	0.481	0.403	2.71E‐04	2.78E‐06	3.11E‐01	2.78E‐06	1.375	1.160	1.629	ZNF536	0
14	rs12589282^a	22937656	G	T	0.535	0.437	6.30E‐06	5.42E‐03	4.11E‐06	4.11E‐06	1.480	1.250	1.752	TRA@	0
3	rs3845905^a	66525963	G	A	0.915	0.850	4.12E‐06	7.45E‐05	3.65E‐04	4.12E‐06	1.894	1.433	2.503	LRIG1	0
5	rs1895302^a	169542600	C	T	0.551	0.478	6.95E‐04	7.41E‐06	4.11E‐01	7.41E‐06	1.340	1.132	1.587	FOXI1	5871
1	rs16825455^a	21837755	T	C	0.686	0.605	8.85E‐05	8.62E‐06	1.90E‐01	8.62E‐06	1.425	1.193	1.702	ALPL	0
Cisplatin
7	rs10253216^a	16861849	T	C	0.565	0.468	2.18E‐03	1.68E‐07	1.00E+00	1.68E‐07	1.478	1.155	1.891	AGR2	−17111
4	rs11944965^a	63424089	T	C	0.807	0.678	3.45E‐06	1.68E‐06	6.65E‐02	1.68E‐06	1.986	1.475	2.676	LOC644534	47600
7	rs7797977^a	16862235	C	A	0.668	0.580	4.06E‐03	5.23E‐01	2.17E‐06	2.17E‐06	1.457	1.127	1.883	AGR2	−17497
18	rs2406342^a	74488280	T	G	0.605	0.475	3.59E‐05	2.48E‐06	6.71E‐02	2.48E‐06	1.697	1.323	2.177	ZNF236	−47836
20	rs6077251^a	7752366	T	C	0.271	0.153	2.50E‐06	3.64E‐06	3.06E‐02	2.50E‐06	2.065	1.537	2.773	SFRS13AP2	59982
8	rs11774576^a	27740417	A	G	0.702	0.581	6.78E‐05	2.82E‐06	2.62E‐01	2.82E‐06	1.699	1.307	2.208	SCARA5	0
11	rs4627050^a	18822037	G	A	0.781	0.649	4.43E‐06	9.01E‐06	2.17E‐02	4.43E‐06	1.932	1.452	2.572	PTPN5	−8648
1	rs12142335^a	108302922	A	G	0.040	0.004	9.91E‐06	8.45E‐06	1.00E+00	8.45E‐06	9.713	3.175	29.710	VAV3	0
Carboplatin
15	rs11071200^a	55950082	T	G	0.060	0.008	1.25E‐06	8.51E‐07	1.00E+00	8.51E‐07	8.241	2.888	23.520	PRTG	0
5	rs3822735^a	35799994	G	A	0.862	0.752	7.24E‐06	1.68E‐06	3.50E‐01	1.68E‐06	2.062	1.500	2.834	SPEF2	0
3	rs1623879^a	58027197	G	A	0.441	0.321	7.69E‐05	1.89E‐02	3.75E‐06	3.75E‐06	1.669	1.297	2.148	FLNB	0
15	rs936229^a	75132319	G	A	0.713	0.595	7.27E‐05	4.41E‐06	3.01E‐01	4.41E‐06	1.685	1.302	2.180	ULK3	0
13	rs7989332^a	21050575	G	T	0.853	0.738	5.47E‐06	1.16E‐04	1.74E‐03	5.47E‐06	2.056	1.507	2.806	CRYL1	0
3	rs3845905^a	66525963	G	A	0.921	0.828	5.99E‐06	2.20E‐05	1.50E‐02	5.99E‐06	2.433	1.645	3.598	LRIG1	0
8	rs1714746^a	4105147	G	A	0.554	0.435	1.59E‐04	6.63E‐02	7.44E‐06	7.44E‐06	1.610	1.261	2.056	CSMD1	0
16	rs12446319^a	81774798	A	G	0.253	0.143	8.97E‐06	1.27E‐04	3.16E‐04	8.97E‐06	2.026	1.480	2.774	CMIP	29431
1	rs1277203^a	109392837	A	G	0.730	0.626	3.50E‐04	3.51E‐02	9.38E‐06	9.38E‐06	1.615	1.243	2.098	AKNAD1	0
All anthracycline‐based drugs
5	rs10040979^a	158424391	G	A	0.701	0.618	4.68E‐03	5.35E‐01	4.60E‐07	4.60E‐07	1.452	1.120	1.883	EBF1	0
2	rs12615435^a	200638509	T	G	0.883	0.773	3.95E‐06	4.09E‐06	9.17E‐02	3.95E‐06	2.214	1.555	3.154	LOC348751	0
5	rs7720283^a	158459721	C	T	0.775	0.706	1.29E‐02	3.37E‐01	4.15E‐06	4.15E‐06	1.431	1.078	1.898	EBF1	0
1	rs1367448^a	68633924	C	T	0.633	0.526	5.02E‐04	5.32E‐06	5.12E‐01	5.32E‐06	1.554	1.212	1.993	LOC100289178	0
6	rs2505059^a	98495952	G	A	0.538	0.398	5.41E‐06	2.29E‐04	2.04E‐04	5.41E‐06	1.765	1.383	2.252	MIR2113	23455
12	rs4149639^a	6442001	C	T	0.120	0.047	7.39E‐06	1.52E‐05	8.16E‐02	7.39E‐06	2.763	1.781	4.287	TNFRSF1A	0
19	rs1654260^a	20329111	A	G	0.625	0.488	8.49E‐06	3.03E‐03	2.18E‐05	8.49E‐06	1.749	1.365	2.240	LOC100421704	−3576
Doxorubicin
15	rs11857176^a	78164706	A	G	0.657	0.515	1.74E‐02	1.00E+00	8.08E‐07	8.08E‐07	1.800	1.127	2.874	LOC100302666	−6274
2	rs4380275^a	773278	G	A	0.392	0.152	4.99E‐06	1.54E‐05	2.05E‐02	4.99E‐06	3.604	2.041	6.365	LOC339822	6559
11	rs2512987^a	86414282	T	C	0.681	0.417	7.02E‐06	6.04E‐03	3.42E‐05	7.02E‐06	2.985	1.855	4.803	ME3	−30604
Epirubicin
12	rs4149639^a	6442001	C	T	0.163	0.042	2.89E‐07	8.31E‐07	3.32E‐02	2.89E‐07	4.443	2.571	7.677	TNFRSF1A	0
5	rs2964475^a	5407814	C	A	0.615	0.415	4.13E‐06	3.95E‐04	1.10E‐04	4.13E‐06	2.248	1.592	3.174	KIAA0947	−14993
13	rs1923834^a	28360487	G	A	0.916	0.770	9.40E‐06	4.61E‐06	3.33E‐01	4.61E‐06	3.236	1.823	5.744	GSX1	−6293
10	rs908366^a	126144839	A	G	0.518	0.328	7.04E‐06	1.08E‐04	8.69E‐04	7.04E‐06	2.199	1.564	3.092	LHPP	−5502
3	rs1553091^a	187716886	G	A	0.452	0.358	2.65E‐02	8.04E‐01	7.46E‐06	7.46E‐06	1.480	1.053	2.080	LOC100505844	−22691
All antimetabolite drugs
18	rs7228133^a	4539085	C	A	0.733	0.686	2.26E‐02	6.64E‐01	1.70E‐06	1.70E‐06	1.255	1.034	1.522	LOC284215	243085
21	rs8127977^a	26826514	A	G	0.804	0.722	1.30E‐05	2.11E‐06	2.67E‐01	2.11E‐06	1.587	1.282	1.966	NCRNA00158	−22501
12	rs894734^a	54319727	G	A	0.849	0.776	3.84E‐05	3.97E‐06	6.63E‐01	3.97E‐06	1.619	1.279	2.050	HOXC13	−12849
13	rs9580312^a	22754093	G	A	0.480	0.409	1.35E‐03	8.09E‐06	6.25E‐01	8.09E‐06	1.330	1.120	1.581	LOC100506622	−30331
21	rs2055011^a	19481354	C	T	0.184	0.143	1.12E‐02	2.12E‐01	8.82E‐06	8.82E‐06	1.347	1.075	1.686	CHODL	−135796
12	rs12582168^a	124894184	C	T	0.333	0.256	8.50E‐05	9.31E‐06	2.84E‐01	9.31E‐06	1.454	1.210	1.748	NCOR2	0
5‐Fluorouracil
7	rs10488226^a	12713070	A	C	0.195	0.107	1.09E‐05	3.54E‐06	2.98E‐01	3.54E‐06	2.026	1.500	2.737	LOC100505995	−12175
2	rs6740660^a	224943685	G	A	0.966	0.894	4.10E‐06	8.83E‐06	2.40E‐01	4.10E‐06	3.386	1.870	6.131	SERPINE2	−39649
4	rs1567482^a	36026747	G	A	0.952	0.875	6.26E‐06	1.44E‐05	9.14E‐02	6.26E‐06	2.846	1.716	4.719	LOC651644	39948
2	rs6706693^a	192465598	A	G	0.328	0.219	1.62E‐05	2.12E‐03	9.45E‐06	9.45E‐06	1.743	1.362	2.232	OBFC2A	−77200
Gemcitabine
18	rs9961113^a	75605399	C	T	0.625	0.403	1.43E‐06	3.83E‐04	3.73E‐05	1.43E‐06	2.473	1.706	3.584	LOC100421527	−260017
5	rs2547917^a	58713680	A	G	0.350	0.212	9.06E‐04	8.79E‐02	3.33E‐06	3.33E‐06	1.997	1.345	2.965	PDE4D	0
15	rs12900463^a	85415386	C	T	0.219	0.115	2.24E‐03	1.02E‐01	4.03E‐06	4.03E‐06	2.154	1.342	3.457	ALPK3	0
22	rs9609078^a	31153276	T	C	0.089	0.009	4.32E‐06	9.97E‐06	2.59E‐01	4.32E‐06	10.890	3.528	33.610	OSBP2	0
5	rs6863418^a	173625154	A	G	0.175	0.055	1.37E‐05	6.98E‐06	4.55E‐01	6.98E‐06	3.623	2.042	6.429	HMP19	88972
20	rs6037430^a	344079	G	A	0.894	0.730	9.74E‐06	1.75E‐05	7.92E‐02	9.74E‐06	3.109	1.805	5.359	NRSN2	8567
All antimicrotubule drugs
17	rs11651483^a	12777402	C	T	0.729	0.665	1.69E‐03	2.60E‐01	3.37E‐07	3.37E‐07	1.357	1.120	1.643	RICH2	0
6	rs4235898^a	77266188	A	G	0.830	0.740	1.05E‐06	3.34E‐06	6.50E‐03	1.05E‐06	1.718	1.377	2.142	LOC100131680	−103976
13	rs4771859^a	93088651	G	A	0.764	0.709	5.49E‐03	2.60E‐01	1.47E‐06	1.47E‐06	1.328	1.088	1.623	GPC5	0
1	rs12145418^a	216716320	T	G	0.334	0.274	3.04E‐03	3.17E‐01	2.35E‐06	2.35E‐06	1.331	1.104	1.604	ESRRG	0
6	rs9386485^a	106329055	T	C	0.596	0.492	2.65E‐06	2.85E‐05	8.59E‐04	2.65E‐06	1.524	1.279	1.817	PRDM1	−205140
16	rs12935229^a	77328895	A	G	0.249	0.182	1.83E‐04	2.23E‐02	4.40E‐06	4.40E‐06	1.495	1.214	1.840	ADAMTS18	0
7	rs6961860^a	17085321	G	A	0.557	0.495	5.33E‐03	8.87E‐01	4.67E‐06	4.67E‐06	1.283	1.078	1.527	LOC100131425	156806
14	rs12882718^a	86902054	T	C	0.737	0.643	5.91E‐06	5.55E‐06	2.03E‐02	5.55E‐06	1.555	1.283	1.884	LOC100421119	−42891
12	rs1043763^a	122630909	T	C	0.668	0.574	1.36E‐05	6.51E‐06	3.10E‐02	6.51E‐06	1.496	1.248	1.795	MLXIP	1920
2	rs4591358^a	196365890	C	T	0.302	0.215	6.60E‐06	6.89E‐04	1.89E‐04	6.60E‐06	1.578	1.297	1.920	LOC391470	81627
14	rs8022296^a	97987857	G	A	0.663	0.608	1.06E‐02	6.54E‐01	7.29E‐06	7.29E‐06	1.269	1.058	1.521	LOC100129345	111127
4	rs6817170^a	154374984	G	A	0.377	0.286	9.29E‐06	4.61E‐05	3.27E‐03	9.29E‐06	1.517	1.264	1.822	KIAA0922	−12514
Paclitaxel
1	rs922106^a	90025519	T	G	0.298	0.202	2.17E‐04	1.95E‐02	9.28E‐07	9.28E‐07	1.679	1.277	2.207	LRRC8B	0
6	rs9386485^a	106329055	T	C	0.624	0.477	1.17E‐06	1.43E‐05	5.24E‐04	1.17E‐06	1.821	1.429	2.320	PRDM1	−205140
8	rs2444896^a	99022009	T	G	0.727	0.603	1.58E‐05	2.43E‐06	7.41E‐02	2.43E‐06	1.754	1.355	2.269	MATN2	0
2	rs4666360^a	20335709	C	T	0.216	0.114	4.62E‐06	3.24E‐06	2.27E‐01	3.24E‐06	2.136	1.546	2.950	RPS16P2	19625
9	rs3138083^a	35648950	A	G	0.220	0.117	3.78E‐06	1.24E‐05	1.09E‐02	3.78E‐06	2.136	1.551	2.942	SIT1	345
17	rs3786094^a	9875205	C	T	0.528	0.422	5.30E‐04	1.80E‐01	5.83E‐06	5.83E‐06	1.531	1.206	1.944	GAS7	0
15	rs4886670^a	75449674	A	C	0.353	0.229	7.26E‐06	5.38E‐05	4.26E‐03	7.26E‐06	1.835	1.412	2.383	RPL36AP45	29318
5	rs792975^a	172271007	T	C	0.654	0.519	7.66E‐06	1.19E‐04	6.08E‐04	7.66E‐06	1.746	1.366	2.232	ERGIC1	0
Docetaxel
9	rs3747851^a	124521260	T	C	0.337	0.176	5.61E‐07	1.12E‐05	5.63E‐04	5.61E‐07	2.377	1.693	3.339	DAB2IP	0
7	rs4727963^a	122759980	C	T	0.772	0.618	7.99E‐06	1.04E‐06	1.69E‐01	1.04E‐06	2.094	1.505	2.914	SLC13A1	0
14	rs1756650^a	87741025	G	A	0.211	0.162	9.95E‐02	9.10E‐01	1.74E‐06	1.74E‐06	1.386	0.954	2.014	GALC	658333
13	rs488248^a	106596719	T	C	0.918	0.795	3.29E‐06	3.23E‐05	1.17E‐02	3.29E‐06	2.896	1.802	4.655	LOC728192	−432192
6	rs12660691^a	130008445	A	C	0.935	0.819	3.62E‐06	4.99E‐06	1.62E‐01	3.62E‐06	3.199	1.899	5.391	ARHGAP18	0
18	rs4553720^a	62170726	T	C	0.377	0.281	7.77E‐03	4.56E‐01	6.77E‐06	6.77E‐06	1.547	1.131	2.116	LOC284294	79890
6	rs2157460^a	130021128	T	C	0.932	0.820	7.07E‐06	1.07E‐05	1.62E‐01	7.07E‐06	3.013	1.806	5.025	ARHGAP18	0
2	rs837841^a	130034012	T	G	0.714	0.662	1.49E‐01	5.26E‐01	8.34E‐06	8.34E‐06	1.279	0.930	1.759	LOC151121	−33653
All topoisomerase inhibitors
5	rs10074959^a	104208013	T	C	0.321	0.237	3.23E‐02	8.08E‐01	1.13E‐06	1.13E‐06	1.524	1.048	2.217	RAB9P1	−227162
7	rs1035147^a	12094966	T	G	0.981	0.877	4.01E‐06	4.75E‐06	5.56E‐01	4.01E‐06	7.294	2.587	20.559	TMEM106B	−155882
1	rs303386^a	99589379	A	G	0.585	0.444	1.10E‐03	4.30E‐06	3.88E‐01	4.30E‐06	1.766	1.256	2.483	LOC100129620	0
14	rs7494275^a	56231800	C	A	0.543	0.406	1.86E‐03	4.26E‐01	8.50E‐06	8.50E‐06	1.732	1.232	2.433	RPL13AP3	−1163
3	rs480409^a	7010081	G	A	0.495	0.348	6.08E‐04	1.63E‐01	9.28E‐06	9.28E‐06	1.842	1.307	2.596	GRM7	0
Camptothecin
6	rs17318866^a	3837198	G	A	0.966	0.790	1.47E‐06	1.78E‐06	1.91E‐01	1.47E‐06	7.559	2.689	21.263	FAM50B	−12434
2	rs17027130^a	41273631	C	T	0.644	0.387	2.54E‐06	8.03E‐04	3.91E‐05	2.54E‐06	2.865	1.844	4.452	LOC729984	−110074
1	rs303386^a	99589379	A	G	0.627	0.429	3.34E‐04	3.61E‐06	1.06E‐01	3.61E‐06	2.238	1.448	3.460	LOC100129620	0
Etoposide
20	rs6039763^a	10183517	A	G	0.370	0.090	1.27E‐05	1.54E‐06	4.61E‐01	1.54E‐06	5.966	2.502	14.230	LOC100131208	0
1	rs2506991^a	48098406	G	A	0.593	0.269	1.39E‐05	1.11E‐02	2.28E‐06	2.28E‐06	3.948	2.101	7.418	LOC388630	127794
2	rs12987465^a	49715021	A	G	0.593	0.359	1.87E‐03	6.26E‐01	6.61E‐06	6.61E‐06	2.597	1.424	4.737	FSHR	–333355
7	rs3095008^a	20255705	T	C	1.000	0.846	1.74E‐05	9.39E‐06	1.00E+00	9.39E‐06	inf	N/A	N/A	MACC1	0
Paclitaxel + carboplatin
12	rs12310399^a	95490248	A	G	0.708	0.567	2.60E‐04	1.08E‐01	2.46E‐07	2.46E‐07	1.852	1.329	2.580	FGD6	0
9	rs10785877^a	137125501	T	C	0.833	0.660	7.38E‐07	1.54E‐05	1.98E‐04	7.38E‐07	2.580	1.766	3.769	RXRA	‐92815
19	rs995834^a	28866596	C	T	0.580	0.425	1.28E‐04	1.20E‐06	1.51E‐01	1.20E‐06	1.871	1.364	2.566	LOC100420587	307385
1	rs922107^a	90022796	G	A	0.323	0.211	1.55E‐03	9.07E‐02	2.73E‐06	2.73E‐06	1.788	1.250	2.558	LRRC8B	0
7	rs1425132^a	37562368	T	C	0.740	0.666	4.55E‐02	7.35E‐01	4.68E‐06	4.68E‐06	1.430	1.013	2.017	LOC442668	62349
1	rs6429703^a	15339960	T	C	0.200	0.078	8.40E‐06	2.59E‐05	5.61E‐02	8.40E‐06	2.942	1.802	4.804	RP1‐21O18.1	0

SNPs used for weighted genetic risk score analyses. BP, SNP genomic location; CHR, chromosome; inf, infinity; L95, lower 95% confidence interval; N/A, not applicable; NRA, non‐risk allele; OR, odds ratio; P_allelic, P‐value from allelic model; P_dom, P‐value from dominant model; P_min, minimum P‐value among the three models; P_rec, P‐value from recessive model; RA, risk allele; RAF, risk allele frequency; rel.loci, distance of the SNP from the gene; U95, upper 95% confidence interval.